Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Entospletinib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    2D Structure
    Also known as: 1229208-44-9, Gs-9973, 6-(1h-indazol-6-yl)-n-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine, Entospletinib [inn], Entospletinib (gs-9973), Gs9973
    Molecular Formula
    C23H21N7O
    Molecular Weight
    411.5  g/mol
    InChI Key
    XSMSNFMDVXXHGJ-UHFFFAOYSA-N
    FDA UNII
    6I3O3W6O3B
    Entospletinib is an orally available inhibitor of spleen tyrosine kinase (Syk), with potential antineoplastic activity. Upon oral administration of entospletinib, this agent may inhibit the activity of Syk, which inhibits B-cell receptor (BCR) signaling and leads to an inhibition of tumor cell activation, migration, adhesion and proliferation. Syk, a non-receptor cytoplasmic, BCR-associated tyrosine kinase, is expressed in hematopoietic tissues and is often overexpressed in hematopoeitic malignancies.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    6-(1H-indazol-6-yl)-N-(4-morpholin-4-ylphenyl)imidazo[1,2-a]pyrazin-8-amine
    2.1.2 InChI
    InChI=1S/C23H21N7O/c1-2-17-14-25-28-20(17)13-16(1)21-15-30-8-7-24-23(30)22(27-21)26-18-3-5-19(6-4-18)29-9-11-31-12-10-29/h1-8,13-15H,9-12H2,(H,25,28)(H,26,27)
    2.1.3 InChI Key
    XSMSNFMDVXXHGJ-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    C1COCCN1C2=CC=C(C=C2)NC3=NC(=CN4C3=NC=C4)C5=CC6=C(C=C5)C=NN6
    2.2 Other Identifiers
    2.2.1 UNII
    6I3O3W6O3B
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. 6-(1h-indazol-6-yl)-n-(4-morpholinophenyl)imidazo(1,2-a)pyrazin-8-amine

    2. Gs-9973

    2.3.2 Depositor-Supplied Synonyms

    1. 1229208-44-9

    2. Gs-9973

    3. 6-(1h-indazol-6-yl)-n-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine

    4. Entospletinib [inn]

    5. Entospletinib (gs-9973)

    6. Gs9973

    7. 6i3o3w6o3b

    8. Chembl3265032

    9. Syk Inhibitor Gs-9973

    10. 6-(1h-indazol-6-yl)-n-(4-(morpholin-4-yl)phenyl)imidazo(1,2-a)pyrazin-8-amine

    11. Imidazo(1,2-a)pyrazin-8-amine, 6-(1h-indazol-6-yl)-n-(4-(4-morpholinyl)phenyl)-

    12. 6-(1h-indazol-6-yl)-n-(4-morpholin-4-ylphenyl)imidazo[1,2-a]pyrazin-8-amine

    13. 6-(1h-indazol-6-yl)-n-[4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine

    14. Entospletinib [usan:inn]

    15. Unii-6i3o3w6o3b

    16. 4puz

    17. Imidazo[1,2-a]pyrazin-8-amine, 6-(1h-indazol-6-yl)-n-[4-(4-morpholinyl)phenyl]-

    18. Gs 9973

    19. Gs9973entospletinib

    20. Gs-9973; Entospletinib

    21. Entospletinib (usan/inn)

    22. Entospletinib [usan]

    23. Entospletinib [who-dd]

    24. Gtpl7889

    25. Schembl2483776

    26. Dtxsid001317670

    27. Hms3653d13

    28. Hms3673e05

    29. Hms3750e13

    30. Amy14224

    31. Bcp09582

    32. Ex-a1120

    33. Bdbm50015448

    34. Mfcd28099806

    35. Nsc781516

    36. Nsc800988

    37. S7523

    38. Zinc98208742

    39. Akos027295322

    40. Ccg-264700

    41. Db12121

    42. Nsc-781516

    43. Nsc-800988

    44. Sb16830

    45. Ncgc00378596-07

    46. Ac-30236

    47. As-17026

    48. Da-36929

    49. Hy-15968

    50. Ft-0700130

    51. Sw220048-1

    52. D11209

    53. A890877

    54. J-690079

    55. Q27077193

    56. Entospletinib;6-(1h-indazol-6-yl)-n-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine

    57. 6-cyclopropyl-8-fluoro-2-[2-(hydroxymethyl)-3-(1-methyl-5-{[5-(4-methyl-1-piperazinyl)-2-pyridinyl]amino}-6-oxo-1,6-dihydro-3-pyridi Nyl)phenyl]-1(2h)-isoquinolinone

    2.4 Create Date
    2012-08-20
    3 Chemical and Physical Properties
    Molecular Weight 411.5 g/mol
    Molecular Formula C23H21N7O
    XLogP33.6
    Hydrogen Bond Donor Count2
    Hydrogen Bond Acceptor Count6
    Rotatable Bond Count4
    Exact Mass411.18075832 g/mol
    Monoisotopic Mass411.18075832 g/mol
    Topological Polar Surface Area83.4 Ų
    Heavy Atom Count31
    Formal Charge0
    Complexity595
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Indication

    Treatment of acute myeloid leukaemia